Common Stock
ADVAXIS INC
NASDAQ:ADXS (12/23/2021, 11:39:10 AM)
0.155
-0.08 (-35.42%)
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 18 full-time employees. The company went IPO on 2005-07-28. The firm is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.
ADVAXIS INC
9 Deer Park Drive, Suite K-1
Monmouth Junction NEW JERSEY 08540
P: 17325451590.0
CEO: Kenneth Berlin
Employees: 18
Website: https://www.advaxis.com/
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced...
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile
Here you can normally see the latest stock twits on ADXS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: